The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial

Nature Medicine 2026 Open access

Read full text
Authors: Scott D. Solomon, John J. V. McMurray, G. Michael Felker, James L. Januzzi, Carolyn S. P. Lam, Adriaan A. Voors, Brian Claggett, T Nuehrenberg, Adel R. Rizkala, C Koch, Wenyue Zhu, Martin P. Lefkowitz
DOI: 10.1038/s41591-026-04313-w
Cited by: 2
References: 22

Abstract

Therapies targeting the natriuretic peptide system have the potential to reduce death or heart failure events in heart failure with reduced ejection fraction. Here we assess XXB750, a human monoclonal antibody activating natriuretic peptide receptor 1, in patients with heart failure. Patients with heart failure and a left ventricular ejection fraction

Fields of Study & Subjects

Heart Failure Treatment and Management Cardiac Fibrosis and Remodeling Receptor Mechanisms and Signaling

Publication details

Journal / source
Nature Medicine
Publisher
Springer Science and Business Media LLC
Volume
32
Issue
5
Pages
1694–1700
Publication date
30 March 2026
Language
EN